Karachi, In a recent financial disclosure, GlaxoSmithKline Pakistan (GLAXO) maintained a stable position in the market without declaring any dividends for the current year. With an EPS of 7.73 for January-February 2024 and a substantial paid-up capital of 3,184.67 million rupees, the company, listed since 1953, continues to play a significant role in providing healthcare solutions, despite facing intense competition and market volatility.